PHARMACOLOGICAL AND DIETARY METHODS TO INFLUENCE THE
INFLAMMATORY STATE OF DAIRY CATTLE
By
Joseph Fehn
A THESIS
Submitted to
Michigan State University
in partial fulfillment of the requirements
for the degree of
Animal Science – Master of Science
2024
ABSTRACT
The replacement rate of dairy cattle is, on average, 35%, while cattle will leave the herd for
reasons other than health events; this rate is not sustainable. Replacement rate can be defined as
the percentage of lactating cows that leave the herd and are replaced by new primiparous cows.
Societal pressure has led to the implementation of a veterinary feed directive (VFD), established
in 2017 to restrict supplementing antibiotics in feed or water to livestock without written consent
from a veterinarian. Then in 2023 further legislation was introduced requiring veterinarian
consent to administer any prescription drugs. While this had little impact on the dairy industry
when first implemented, the aim of the VFD is to lessen the likelihood of further microbial
antibiotic resistance in livestock production. To help improve the resilience of cows to
pathogens, research has been done to investigate naturally occurring compounds that may help
decrease the need for antibiotic use. β-Caryophyllene (BCP) has been demonstrated to possess
anti-inflammatory properties. In this experiment, 20 mid or late lactation dairy cows, enrolled
using a randomized complete block design, received two lipopolysaccharide (LPS)
intramammary challenges 28 days apart and received 1 of 2 treatments for 42 days: 1) CON
(basal TMR); 2) BCP, consisting of 5 mg/kg of body weight, as liquid BCP delivered as a top
dress treatment and mixed in with the top 20% of the ration. No changes in dry matter intake,
body weight, milk yield or components were observed between treatment groups. BCP
supplementation resulted in a lower haptoglobin concentration during the first LPS challenge and
a lower somatic cell count (SCC) prior to the second LPS challenge. Plasma haptoglobin
concentrations were lower in the second LPS challenge and a higher peak in SCC was observed
in BCP cows. I conclude that supplementation of BCP during a LPS intramammary challenge
lessens the systemic inflammatory response experienced by late lactation dairy cows.
ACKNOWLEDGEMENTS
I would like to first thank Dr. Barry Bradford for all his patience and never-ending
support while I finished this degree. I would also like to thank Dr. Laman Mamedova for all the
support, surprises, and remedies for any illness I had as she was always a bright spot through
some dull times. I would also like to thank my committee members, Dr. Abuelo, Dr.
Templeman, and Dr. Zhou for all their support while I’ve completed my program.
I’d also like to acknowledge all my fellow lab mates who all provided support whenever
needed. Also, a special thanks to the undergraduates who helped me during my research trial,
and the MSU dairy farm and staff for allowing us to conduct research.
Above all, I would like to give a special thanks to Brian Heman and AgOasis. If it
weren’t for Brian allowing me to work at one of his dairies after dropping out of school, I don’t
think that I would be here today. Thanks to my experience at the dairy, I discovered my passion
for dairy cattle, and my desire to help and teach others.
Overall, I am thankful to everyone who has been in my life during my graduate studies –
my parents, fellow graduate students, other Animal Science faculty, and friends from all around.
I would also like to give a special thanks to Isabelle Bernstein for all of her undying support and
helping me survive grad school. You all have made this experience such a wonderful and
memorable time. Although many of my biggest supporters have not been in Michigan, or always
understand what I’m studying, they have continued to provide undying support and I couldn’t
have done it without them.
iii
TABLE OF CONTENTS
CHAPTER 1: REVIEW OF THE LITERATURE......................................................................... 1
CHAPTER 2: EFFECTS OF β-CARYOPHYLLENE SUPPLEMENTATION ON DRY
MATTER INTAKE AND PRODUCTIVITY OF LATE-LACTATION DAIRY COWS
THROUGH REPEATER LIPOPOLYSACCHARIDE CHALLENGES..................................... 18
CHAPTER 3: IMPLICATIONS AND CONCLUSIONS............................................................ 34
BIBLIOGRAPHY......................................................................................................................... 37
APPENDIX................................................................................................................................... 48
iv
CHAPTER 1:
REVIEW OF THE LITERATURE
1
Introduction
In the U.S. dairy industry, there is an average lactating cow replacement rate of 35%
(Overton and Dhuyvetter, 2020). Replacement rate can be defined as the percentage of lactating
cows that leave the herd and are replaced by new primiparous cows. Often cows are replaced for
reasons other than health events, but regardless of the cause, this replacement rate is far from
optimal in terms of economic, social, or environmental sustainability (Murat Tatar et al., 2017).
Mastitis and metritis are common infections experienced by dairy cattle and can often require
antibiotic treatment (Cheng and Han, 2020). Due to societal pressure, a veterinary feed directive
(VFD) was established in 2017 to restrict supplementing antibiotics in feed or water to livestock
without written consent from a veterinarian, then further legislation was passed in 2023 to
require a veterinarian prescription for any antibiotics. While this had little impact on the dairy
industry when first implemented, the aim of the VFD is to lessen the likelihood of further
microbial antibiotic resistance in livestock production. To help improve the resilience of cows to
pathogens, research has been done to investigate naturally occurring compounds that may help
decrease the need for antibiotic use. This review of the literature will examine the mechanisms of
inflammation and common pharmaceutical and dietary methods to modulate the inflammatory
state of the dairy cow.
Inflammation during an immunological challenge
Inflammation is part of the innate immune system that is commonly associated with
localized heat, swelling, pain, and a reduction in appetite (Vane and Botting, 1987).
Inflammation consists of three phases: alarm, mobilization, and resolution. The acute
inflammatory response is activated when pattern recognition receptors (PRR) detect either
pathogen-associated molecular patterns (PAMP) or damage-associated molecular patterns
2
(DAMP). PAMP consist of microbial nucleic acids, lipoproteins, and carbohydrates (Mogensen,
2009). PRR are found on both tissue-resident immune cells like macrophages, mast cells, and
dendritic cells, as well as on leukocytes and many non-immune cells. Upon PRR activation, there
is an increase in expression of pro-inflammatory mediators, including cytokines and chemokines,
aiding in the recruitment of leukocytes and production of complement proteins, adhesion
molecules, histidine, and eicosanoids (Newton and Dixit, 2012). Transcription factors such as
nuclear factor kappa B (NFκB) and activator protein-1 (AP-1) are found in the cytoplasm of cells
and are activated thorough extracellular signaling (Adcock and Caramori, 2009). These
transcription factors coordinate the activation of many genes, including proinflammatory
cytokines (Schottelius et al., 1999; Hoffmann and Baltimore, 2006). Depending on the pathogen
load, NFκB and/or AP-1 will trigger positive or negative feedback, thus allowing the body to
mount an appropriate response to the pathogen load (Adcock and Caramori, 2009; Sung et al.,
2014). Inflammatory cytokines include tumor necrosis factor α (TNFα), interleukin (IL)-1 and
IL-6 (Takeuchi and Akira, 2010). Histidine and adhesion molecules work together with the
increased blood flow to allow for neutrophils to enter the site of irritation. This passage of
neutrophils across the vascular epithelium is the cause for heat, swelling, and pain associated
with inflammation (Sordillo, 2018). If the acute response is adequate, the body switches from
producing prostaglandins (pro-inflammatory mediators) to lipoxins that aid in the recruitment of
macrophages and begin tissue repair (Medzhitov, 2008). If the initial inflammatory response is
unable to resolve the irritation, the neutrophil cascade is accompanied by macrophages and T-
cells (Medzhitov, 2008). Once the body has successfully eliminated the pathogen, it will switch
from pro-inflammatory to resolving signaling by producing cytokines such as IL-4, IL-10, IL-11
and IL-13. Interleukins IL-4 and IL-10 aid in the attenuation of inflammatory transcription
3
factors (Schottelius et al., 1999; Iribarren et al., 2003). If the body cannot eliminate the pathogen,
it is possible that granulomas and tertiary lymphoid tissues can form (Medzhitov, 2008). The
inflammatory response is the first step in a immune response and may either be isolated and
resolved or may require other branches of the immune system to intervene to help clear the
pathogen.
Oxidative status
Oxidants consist of substances able to oxidize other molecules (Abuelo et al., 2015). Free
radicals are atoms or molecules that have one or more unpaired electrons in their outer electron
shell, and are oxidizing agents (Sordillo and Aitken, 2009). Reactive oxygen species (ROS) are a
class of free radicals that are produced from superoxide anions as a byproduct of cellular
metabolism, and produced by activated neutrophils and macrophages (Sordillo and Aitken, 2009;
Abuelo et al., 2015). These superoxide anions can interact with other molecules to generate
various ROS (Sordillo and Aitken, 2009). ROS aid in the host immune response by promoting
the expression of cytokines and eicosanoids, as well as through the destruction of phagocyted
pathogens (Abuelo et al., 2015). Antioxidants may be synthesized within the host, or may be
consumed in the diet, and are generally described as any substance that prevents, delays, or
removes oxidative damage (Sordillo and Aitken, 2009). Examples of antioxidants include
vitamin E and selenium (Miller et al., 1993; Finch and Turner, 1996). Antioxidants and ROS
work together to maintain the oxidative status of the host. However, when abundant ROS are
produced and there are insufficient antioxidants present, the condition called oxidative stress
develops (Abuelo et al., 2015). Oxidative stress can cause tissue damage and deteriorate cell
membrane integrity and may even result in cell death (Abuelo et al., 2015; Bradford et al., 2015).
Oxidants in themselves are harmless, but if the oxidative status shifts towards a high
4
concentration of ROS damage can occur to the host. In order to balance the oxidative status of
cattle, it is important to limit ROS production, and or provide sufficient antioxidants to offset
ROS production.
Inflammation during the transition period
The transition period poses an interesting challenge to both dairy producers and
nutritionists, leading to it being studied extensively. During the last week preceding parturition,
the dairy cow begins to back off feed intake while initiating colostrogenesis. Parturition is
associated with tissue damage, and an immediate increase in energy demands due to lactogenesis
(Bradford et al., 2015). The combination of already expressing feed adverse behavior and new
tissue damage following parturition provides the perfect storm for other insults to the immune
system. This could explain why this period often accounts for most illness events on a dairy
farm, especially for mastitis and metritis (Barragan et al., 2021). This predicament has led to the
search for methods to influence the inflammatory state during this period so that the cow may
return to consuming adequate feed more quickly than a cow with no intervention. Studies have
shown mixed results when attempting to alter the inflammatory state during the transition period;
some show an increase in milk yield (Bertoni et al., 2004; Barragan et al., 2021). Others
observed an increase in the rate of dystocia when flunixin was administered pre-calving and an
increase in retained placentas when administered post-calving (Newby et al., 2017). While
inflammation during the transition period is responsible for most illness events on a dairy,
influencing the inflammatory state is more complex than just reducing inflammation around
calving.
5
Mastitis
Mastitis, which consists of inflammation of the mammary gland, results in roughly 2
billion dollars lost annually in the U.S dairy industry (Cha et al., 2011). Mastitis is either
contagious or environmental (coliform) but both result in lower fluid milk production, milk
component concentrations and an increase of milk immunoglobulins due to increased
permeability of the blood-milk barrier, and may cause tissue damage (Ogala et al., 2007).
Mastitis cases can be clinical or sub-clinical. A clinical case of mastitis results in the clinical
signs of inflammation in the udder accompanied by watery milk with visible flakes and clots,
whereas sub-clinical mastitis demonstrates no visible signs of udder inflammation, but a decrease
in milk production and increase in the somatic cell count (SCC) (Cheng and Han, 2020).
Symptoms experienced during clinical mastitis may be local, with only heat and redness in the
infected quarter, or may be more severe, causing systemic fever and a reduction in feed intake
(Cheng and Han, 2020).
Coliform bacteria are able to survive in near anaerobic conditions and are able to utilize
lactose as a fuel source, allowing them to proliferate within the mammary gland (Hogan and
Smith, 2003). The low oxygen concentration in the mammary gland can inhibit production of
ROS like hydrogen peroxide, used by neutrophils to help kill/breakdown pathogens, thus
compromising the host’s immune defense (Sordillo and Streicher, 2002). Contagious bacteria
may originate from the bedding area or on milk machines as a result of poor milking hygiene
(Smith et al., 1985). Once a cow is infected with contagious bacteria, the udder becomes the
major reservoir and the bacteria is primarily spread between cattle while milking; these
pathogens tend to result in chronic sub-clinical infections with occasional flares of clinical cases
(Abebe et al., 2016). Factors such as age, breed, and udder structure can increase a cow’s
6
susceptibility to mastitis and paired with reduced immune function due to low oxygen
concentrations, the mammary gland may be unable to clear the infection on its own, thus
requiring antibiotic intervention (Cheng and Han, 2020). Mastitis, regardless of type, results in
profit loss to the producer through lowered milk production and sometimes treatment costs.
Thus, management practices to limit the spread of environmental infections or other anti-
infection interventions should be used to help limit milk withdrawal times to help minimize loss
of profit by producers.
Methods to modulate the inflammatory state in dairy cattle
Inflammation is commonly associated with illness, but it is not inherently bad for the
host. Often, inflammation is necessary, like during parturition or when fighting off infection
(Medzhitov, 2008; Bradford et al., 2015). By inhibiting specific enzymes or pathways using anti-
inflammatory drugs, not only are the clinical signs of inflammation lessened, but the response to
pathogens can also be delayed. It has been demonstrated that inhibiting key functions of
inflammation pre-partum can result in increased stillbirth rate as well as an increased odds of
clinical signs of inflammation, metritis, retained placenta, and a decrease in milk production
(Newby et al., 2017). As different methods to modulate inflammation are discussed in this
chapter, it is important to keep in mind what the potential adverse effects of blindly blocking
pathways may be.
Trained immunity. One method for immunomodulation is innate memory, where innate
immune cells demonstrate either an enhanced or suppressed response to a repeated immune
challenge (Byrne et al., 2020). Innate immunity can be thought of as the instant and non-specific
response arm of the immune system, which has traditionally been considered to be incapable of
developing an immunological memory. Adaptive immunity, in contrast, is able develop a
7
memory response to pathogens, allowing for a more targeted and heightened immune response.
This greater immune response is achieved through the production of memory B and T cells that
allow for long-term protection against the same pathogen (Chaplin, 2010). Trained immunity
works as a protection against reinfection independent of memory B and T cells. Instead, trained
immunity works through other cells, such as natural killer cells, and is achieved through
epigenetics (altering gene expression without DNA sequence modulation) and metabolic
programming (Byrne et al., 2020). Adaptive immunity can be distinguished from trained
immunity by the pathogen specificity and duration of immunity. Adaptive immunity is highly
specific to the pathogen and provides long-term immunity (years-lifetime); conversely, trained
immunity is often non-specific and provides short term altered immunity (Netea, 2013). LPS is
one of the best-known innate priming agonists able to alter the immune system, and has been
demonstrated to alter the immune system response to repeated challenges in a dose-dependent
manner (Byrne et al., 2020). When LPS is administered in low doses, tolerance is observed
(Yoza and McCall, 2011); however, administration of even lower concentrations results in
heightened immune responses (Ifrim et al., 2014). In a bovine mastitis model, repeated LPS
challenges with an interval of 14 days resulted in a lower concentration of immune indicators in
the plasma as well as milder local signs of inflammation (Suojala et al., 2008). In another study,
cattle received an intramammary infusion of LPS and were later challenged with Escherichia
coli. Cows who had received the LPS infusion demonstrated lesser signs of systemic and local
inflammation (Petzl et al., 2012). Other forms of innate priming agonists include β-glucans and
bacilli Calmette-Guérin (BCG), a live attenuated vaccine for tuberculosis (Byrne et al., 2020).
One study demonstrated that monocytes isolated from calves who received the BCG vaccine
produced more pro-inflammatory cytokines when stimulated with LPS and Pam3CSK4,
8
compared to cells isolated from non-vaccinated calves (Guerra-Maupome et al., 2019). Trained
immunity poses as a short-term method to lessen the inflammatory response to non-specific
inflammatory markers such as LPS.
Selective and non-selective cyclooxygenase inhibitors. One class of anti-inflammatory
drugs are the cyclooxygenase (COX) inhibitors, also commonly known as nonsteroidal anti-
inflammatory drugs (NSAID). COX inhibitors are commonly used in the dairy industry and are
readily available as over-the-counter (OTC) drugs. The COX enzymes (COX 1 & COX 2)
catalyze the rate-limiting step in biosynthesis of many eicosanoids, including prostaglandins
(Chandrasekharan and Simmons, 2004). COX-1 is expressed at a relatively constant rate and
plays a role in homeostasis, whereas COX-2 expression is associated with inflammation and is
stimulated by LPS, IL-1, IL-2, and TNFα (Vane et al., 1998). In the gastrointestinal tract,
prostaglandins from COX-1 aid in the production of the mucosal lining. The available COX
inhibiting drugs are either selective to COX-1 or COX-2 or nonselective, inhibiting both
enzymes. Examples of selective COX inhibitors include carprofen, meloxicam, and tolfenamic
acid; non-selective COX inhibitor examples include flunixin and ketoprofen (Breen, 2017).
COX-2 inhibition during an immune challenge reduces the fever response, along with mitigation
of negative effects on dry matter intake (DMI) during an immune challenge, dependent upon the
half-life of the drug administered (Yeiser et al., 2012).
COX inhibitors have been studied as potential tools for resolution of acute coliform
mastitis cases. Orally administered non-selective inhibitors such as aspirin, ketoprofen, and
flunixin meglumine should be used with caution, as excessive COX-1 inhibition around
parturition may increase the risk of retained placenta, culling, or metritis (Trimboli et al., 2020).
9
COX inhibitors have been shown to lower the SCC in cattle experiencing mastitis (Anderson and
Hunt, 1989), reduce body temperature (Morkoç et al., 1993), and improve the recovery from
clinical mastitis cases (Shpigel et al., 1994). When considering usage of COX inhibitors, there is
a meat and milk withhold time of 24 hours or more (Smith et al., 2008). COX inhibitors may
blunt the inflammatory response and its effects on DMI and production. When administering
COX inhibitors, selective COX-2 inhibitors should be considered as excessive COX-1 inhibition
may have deleterious effects around parturition.
Glucocorticoids and prostaglandins. Glucocorticoids (GC) are a class of anti-
inflammatory mediators synthesized in the adrenal cortex. Adrenal GC production is regulated
by the hypothalamic-pituitary-adrenal axis (Timmermans et al., 2019). During an immunological
challenge, cytokines stimulate the hypothalamus, causing the release of corticotropin-releasing
hormone; in turn, corticotropin is released from the anterior pituitary. Corticotropin then acts on
the adrenal cortex to trigger synthesis and secretion of cortisol, which is then converted to
cortisone (Rhen and Cidlowski, 2005). GC secretion inhibits inflammation via the
downregulation of chemokine and cytokine activity, inhibition of eicosanoid production from
macrophages, and inhibition of endothelial production of intercellular and vascular adhesion
enzymes (Cain and Cidlowski, 2017). GC activate glucocorticoid receptors and can inhibit
prostaglandin production through the inhibition of annexin I, MAPK phosphatase 1, and COX-2
(Rhen and Cidlowski, 2005). Inhibition of these pathways ultimately results in anti-inflammatory
and analgesic effects.
There are many synthetic GC that are widely available, such as prednisone, prednisolone,
and dexamethasone. When treating acute cases of mastitis, administration of GC such as
dexamethasone can result in lower body temperatures as well as less milk production loss than
10
an untreated cow with mastitis (Lohuis et al., 1988). Prednisone may decrease the production of
pro-inflammatory cytokines and decrease SCC, depending on the type of infection (Wall et al.,
2016). Because treatment with GC may lessen immune responses, it may impair the immune
system’s ability to resolve the infection due to impaired immune cell migration (Roth, 1982). GC
supplementation during an immune challenge may reduce the inflammatory response, but should
be used with caution as the reduction in inflammatory response may also lessen the host’s ability
to clear the pathogen thus prolonging the infection.
Omega-3 fatty acids. During an immune challenge, immune cells can utilize FA,
glutamine, or glucose as fuel sources (Sordillo, 2016). Immune cells utilize these energy sources
at varying rates depending on severity of immune challenge and DMI (Calder, 2013). Oxylipids
are synthesized from substrates including omega-6 linoleic and arachidonic acids and omega-3
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA; Sordillo and Raphael, 2013).
Commonly, omega-6 FAs activate NFκB and enhance inflammatory responses, whereas omega-
3 FAs tend to inhibit NFκB and promote resolution of inflammation (Serhan, 2009; Calder,
2012). DHA and EPA demonstrate anti-inflammatory functions by inhibiting NFκB activation
indirectly by altering the concentrations of inflammation mediators such as prostaglandin F 2α
(Badinga and Caldari-Torres; Lee et al., 2010; Calder, 2012). It has been demonstrated that
increasing the omega-3 FA content of endothelial cells can lessen their pro-inflammatory
response (Contreras et al., 2012). By altering the omega-6 to omega-3 ratio of FA supplemented
to dairy cattle, it may be possible to lessen the inflammatory state during times such as the
periparturient period or during mastitis (Bradford, 2020). When feeding diets differing in the
ratio of omega-6 and omega-3 acids, increasing omega-3 supply led to an increase in DMI and
milk component yields as well as a decrease in the acute phase response to an intramammary
11
LPS challenge. However, increasing the amount of omega-3 in the diet did not attenuate the
decrease in DMI during an immune challenge (Greco et al., 2015). By altering the FA supplied
in the diet to a higher concentration of omega-3 acids, the body may produce less pro-
inflammatory mediators during an infection. Feeding omega-3 acids serves as a preventative
measure to lessen the inflammatory state, but during an active infection, other interventions may
be required to help clear up the cause of infection.
Phytogenics. As demonstrated by the VFD of 2017, the use of feed antibiotics in
livestock has become a greater consumer concern, leading to the interest in naturally occurring
compounds that may support immune system function to reduce the need for antibiotic treatment
of disease and limit the risk of antibiotic resistance in livestock. Phytogenics refers to a broad
array of secondary metabolites produced by plants (Swartz and Bradford, 2023). Phytogenics
have been studied as a dietary method to decrease methanogenesis (Sinz et al., 2019). Ku-vera et
al. (2020) demonstrated that some tannins, saponins, free phenolics, and flavonoid compounds
inhibit methane production from ruminal fermentation (Ku-Veraet al., 2020).This review is
going to discuss primarily one class of these naturally occurring compounds, polyphenols, which
exert antioxidative and immunostimulatory effects. Polyphenols are a group of over 8,000
compounds, all containing phenol rings. Polyphenols can be further divided into flavonoids and
other phenolic acids. It is worth noting that the concentration of plant polyphenols is highly
dependent on the maturity and part of the plant that is fed (Miranda et al., 2014). Because plant
secondary metabolites are more difficult to patent than synthetic compounds, there has been
limited private sector investment in these compounds. The limited literature, in turn, means that
for most polyphenols, there is no standard dose recommendation, and publications vary widely in
doses administered (Soltan et al., 2023). Phytogenics pose as a natural solution to combat
12
inflammation while avoiding the adverse effects of animal product withhold times due to
treatment.
Flavonoids. Flavonoids are a class of polyphenols known to have anti-inflammatory and
antioxidative functions. Flavonoids are made up of a three-ring core and are divided into five
subgroups: flavanols, anthocyanidins, flavones, flavanones, and chalcones (Middleton et al.,
2000). Even though there are thousands of known flavonoids, they almost all promote broad anti-
inflammatory effects on different cell types (Gonzálezet al., 2011). Classically, flavonoids have
been studied in ruminants as a tool to decrease methane production (Sinz et al., 2019; Ku-Vera et
al., 2020). While research is limited, groups have set out to analyze flavonoid supplementation
during the transition period and mastitis challenges (Olagaray and Bradford, 2019).
Morin is a flavonoid isolated from the mulberry/fig family of plants (Moraceae) and has
been demonstrated to help lessen the inflammatory response to bovine mammary epithelial cells
during LPS-induced mastitis in a cell culture model. Morin acts through inhibition of the NF-κB
pathway (Wang et al., 2016). Supplementing silymarin (extracted from milk thistle) pre- and
post-partum tended to lower the SCC in cows during the first 21 DIM as well as lead to increased
milk production and no noticeable change in milk composition (Tedesco et al., 2004; Garavaglia
et al., 2015). Another group looking at supplementing a cocktail of flavonoids to lactating cattle
with moderate or high SCC found that supplementation lowered SCC in cows with high SCC but
had no effects on moderate SCC. An increase in DMI, fluid milk, and feed efficiency was also
observed (Hashemzadeh-Cigari et al., 2014). Flavanoid supplementation may help reduce the
inflammatory state, but further research needs to be done looking at the effects during an active
infection.
13
Other phenolic acids. Another group of phytogenic compounds are other phenolic acids,
including free phenolics, essential oils (EO), lignans, saponins, terpenes, quinones, and alkaloids
(Swartz and Bradford, 2023; Worku and Ismail, 2020). Essential oils are a liquid and volatile
form of secondary metabolites. Supplementation of non-flavonoid polyphenols in diabetic
murine and human models decreased the concentration of pro-inflammatory molecules (Miranda
et al., 2014). EO found in ginger have been used as folk medicine for the treatment of pain and
inflammation (Worku and Ismail, 2020). Eugenol is an EO found in clove oil, nutmeg,
cinnamon, and basil which has demonstrated anti-inflammatory effects (Fujisawa et al., 2002;
Carrasco et al., 2009). Phenolic compounds found in plants may be polymerized into larger
molecules such as proanthocyanidins (condensed tannins) and lignins (Waghorn and McNabb,
2003). Feeding birdsfoot trefoil (a forage with high concentrations of tannins) to lactating dairy
cows improved feed efficiency, increased milk yield and milk protein yield, but also decreased
milk fat concentration (Woodward et al., 1999; Harris et al., 1998). Hydroxycinnamic acids are
free phenolic acids with the most common ones including caffeic acid, ferulic acid, p-coumaric
acid, sinapic acid, and chlorogenic acid (Chen and Ho, 1997). Using inflammatory bowel disease
as a model of inflammation, Zielińska et al. (2021) observed that caffeic acid exerts anti-
inflammatory properties by targeting COX-2 and PGE2 (Zielińska et al., 2021). Supplementation
of phenolic acids may serve as a preventative measure to inflammatory responses, but much like
omega-3 supplementation, other methods may be required to clear a pathogen in the event of an
active immune challenge.
Endocannabinoid system. Endocannabinoids, closely related to oxylipids, are a class of
lipid mediators (Walker et al., 2022). Endocannabinoids are derived from arachidonic acid and
synthesized in the body, while phytocannabinoids are synthesized in plants and are only active in
14
mammals after ingestion (Chayasirisobhon, 2021). Phytocannabinoids have properties similar to
cannabinoids and/or interact with the cannabinoid receptors (Gertsch et al., 2010). Examples of
endocannabinoids include anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), and
examples of phytocannabinoids include β-caryophyllene (BCP), cannabidiol (CBD) and Δ9-
tetrahydrocannabivarin (THCV) (Bolognini et al., 2010; Gertsch et al., 2010). The
endocannabinoid system (ECS) is activated by two receptors - CB1 and CB2 - and is involved in
metabolism, energy homeostasis, and inflammation (Zachut et al., 2018). The CB1 receptor is
associated with the central nervous system and is responsible for the psychoactive effects such as
catalepsy and memory/cognitive impairment reported with some cannabinoids (Pertwee and
Ross, 2002a; Aly et al., 2020). In contrast, CB2 activation is associated with peripheral and
immune cell responses (Pertwee and Ross, 2002). Both the CB1 and CB2 receptors can be found
in immune cells (macrophages, dendritic cells and B cells), but the CB2 receptors are 10-100
times more abundant than CB1 in these cell types (Ziring et al., 2006; Chiurchiù et al., 2015;
Rahaman and Ganguly, 2021).
CB2 activation has been demonstrated to exert anti-inflammatory effects in vitro and vivo
(Gertsch et al., 2008). During infection, endocannabinoid production is increased, paired with a
downregulation of the AEA-degrading enzymes (Klein, 2005). Depending on both the
concentration and timing, endocannabinoids may serve as pro- or anti-inflammatory signals
(Basu and Dittel, 2011; Walker et al., 2022b). CB2 aids in reducing the inflammatory state by
inhibiting the release of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α (Correa et
al., 2009; Capozzi et al., 2022). During LPS activation of the immune system, CB2 agonists
inhibit the secretion of TNF-α and IL-1β (Gertsch et al., 2008; Jürg Gertsch and Gertsch, 2017).
Endocannabinoids function as lipid mediators, thus increasing the dietary supply of
15
endocannabinoids may act as a preventative method to the inflammatory response, but once
again, other interventions may be required in the event of an immune challenge.
β-caryophyllene. BCP is a sesquiterpene phytochemical that is relatively abundant in
plants such as black pepper, oregano, and cinnamon (Gertsch et al., 2008). BCP selectively
activates the CB2 receptor and has been shown to have analgesic, anti-inflammatory (lower
production of TNF-α, IL-1β, IL-6 and NF-κB), and other immunomodulatory effects (Klauke et
al., 2014; Francomano et al., 2019; Scandiffio et al., 2020). BCP stimulation of the CB2 receptor
has been demonstrated in cell culture models stimulated with LPS, and when cells were treated
with a CB2 antagonist the positive effects of BCP were reverted (Picciolo et al., 2020). In
another study, researchers found BCP treatment exerted anti-inflammatory effects and decreased
the oxidative status of cells exposed to a conditioned medium from activated monocytes
(Mattiuzzo et al., 2021). In murine models, oral supplementation of BCP demonstrated a 70%
reduction of carrageenan-induced paw edema (Gertsch et al., 2008). In another murine model,
oral BCP supplementation suppressed the expression pro-inflammatory cytokines in the context
of antiretroviral drug-induced neuropathic pain (Aly et al., 2020). BCP, a dietary cannabinoid,
may help blunt the response to an immune challenge. Before BCP can be recommended for
commercial use, further studies need to be conducted to define an effective dose, as well as
confirm that there are no residuals found in meat or milk products.
Conclusions
Inflammation is an essential part of homeostasis, but too much inflammation can impede
lactation performance (Bradford et al., 2015). Although compounds have been identified which
can influence immune responses, there are few tools that are proven effective for enhancing
resilience to disease challenges. Supplementation of phytogenic compounds such as BCP may
16
potentially decrease pro-inflammatory signals (Klauke et al., 2014) so that a healthy degree of
inflammation is still allowed while not completely eliminating its effects. BCP selective
activation of the CB2 receptor is of primary interest, as this avoids potential psychotropic effects
while providing all of the anti-inflammatory effects (Scandiffio et al., 2020). While BCP has
been shown effective in murine and cell culture models (Gertsch et al., 2008; Mattiuzzo et al.,
2021), the effect of BCP supplementation on dairy cattle in an LPS mastitis model is pertinent to
further understanding its effects on inflammation.
17
CHAPTER 2:
EFFECTS OF β-CARYOPHYLLENE SUPPLEMENTATION ON DRY MATTER INTAKE
AND PRODUCTIVITY OF LATE-LACTATION DAIRY COWS THROUGH REPEATER
LIPOPOLYSACCHARIDE CHALLENGES
18
Abstract
Inflammation greatly impacts the health and performance of dairy cows during lactation.
The objectives of this study were to evaluate the effect of β-caryophyllene (BCP) supplementation
on somatic cell score (SCS) and inflammatory blood markers in late lactation dairy cattle
experiencing an acute mastitis challenge, as well as carryover effects of a second mastitis
challenge. Twenty late lactation Holstein cows (240 ± 60 DIM; 33 ± 6.9 kg/d of milk) were
enrolled in a randomized complete block design experiment lasting 70 d. Cows were assigned
treatments of no top-dress (CON, n = 10) or BCP (n = 10) consisting of 5 mg/kg BW liquid BCP
added as a top-dress as a top dress treatment and mixed in with the top 20% of the ration. All cows
received the same diet. Cows were challenged in the right-rear quarter (RR) with 10 µg of
lipopolysaccharide (LPS) on d 28 and d 56. Quarter-level milk (RR) was collected at 0, 8, 16, 24,
48, 72, 96, 120, 144, and 168 h after each LPS challenge. Treatment effects were determined using
linear repeated mixed models in SAS, including fixed effect of treatment, time, parity, and their
interactions and random effects of block and cow. Before LPS, BCP did not affect DMI, milk
yield, milk composition, SCS, or plasma glucose concentration (all P > 0.10). After each LPS
challenge, BCP did not affect DMI, milk yield or composition, but reduced composite milk SCS
(P < 0.01) A treatment × time interaction (P < 0.001) for SCS revealed a tendency for more
complete resolution in BCP-treated cows at d 52 (P = 0.06). Conversely, SCS in the RR quarter
was greater for BCP vs. CON (P = 0.02) at 16 h after challenge 2 (treatment × time: P < 0.001).
Plasma haptoglobin was significantly reduced by BCP in the 5 d following challenge 1 (P = 0.02)
but not challenge 2 (P > 0.10). Overall, results suggest that BCP supplementation may reduce the
inflammatory response observed from acute mastitis. Further work is required to understand the
underlying mechanisms of the changes observed in this study.
19
Introduction
Nutritional methods to influence the inflammatory state of dairy cattle have been a strong
area of interest in the research community. Improving the understanding and delivery of
nutraceuticals has the ability to further dairy production while working towards economic and
environmental sustainability. The use of nutraceuticals may reduce the need for other
pharmaceuticals, thus lowering the quantity of dairy products that are unusable due to drug
withdrawal times from products.
Phytocannabinoids, such as β-caryophyllene (BCP), are secondary plant metabolites that
have similar properties to endocannabinoids and/or interact with the cannabinoid receptors
(Gertsch et al., 2010). BCP has been proposed as a nutrient potentially capable of reducing
inflammation through its selective activation of the CB2 receptor (Francomano et al., 2019).
BCP is also known to have antioxidant, neuroprotective, anxiolytic, anti-cancer, and analgesic
effects (Aly et al., 2020). The CB2 receptor is widely found among immune cells, modulating
cytokine release and immune cell migration (Pertwee, 2006). Unlike the CB1 receptor, it
provides these results without psychoactive effects. Activation of the CB2 receptor through
agonists can reduce inflammation by inhibiting the release of inflammatory cytokines such as IL-
6, IL-8, IL-1β and TNF-α in LPS-stimulated monocytes (Capozzi et al., 2022; Correa et al.,
2009; Gertsch et al., 2008; Jürg Gertsch & Gertsch, 2017). BCP supplementation, therefore, may
help lessen the inflammatory state experienced by a dairy cow during an immunological
challenge through its relationship with the CB2 receptor.
While not previously studied in dairy cattle, BCP supplementation has been studied in
multiple murine models. Oral supplementation in mice models has demonstrated suppression of
pro-inflammatory cytokines (Aly et al., 2020) and a decrease in paw edema (Gertsch et al., 2008)
20
in different inflammatory models. Poulopoulou & Hadjigeorgiou (2021) suggest that the rumen
microbiome takes 1 week to adjust to BCP supplementation; after adaptation, the mean ruminal
degradation rate was just 4.3% per h (compared to 0.1% in PBS solution) using an ovine model.
In comparison to expected ruminal liquid outflow rates in dairy cattle of ~19% per h (Taylor et
al., 2005), these findings point to a strong potential for BCP delivery to the small intestine.
Trained immunity is the process in which innate immune cells undergo epigenetic
changes resulting in either an enhanced or suppressed response to a repeated immune challenge
(Byrne et al., 2020). Unlike adaptive immunity, trained immunity provides short term, often non-
specific alteration of immune function (Netea, 2013). The concept of trained immunity raises a
question: if innate immunity can be trained from a primary challenge, can what is consumed
during a primary infection impact the body’s trained response to a repeated challenge?
The objectives of this experiment were to evaluate if BCP supplementation reduces the
SCS and inflammatory blood markers in late lactation dairy cattle experiencing an acute mastitis
challenge. Additionally, we investigated carryover effects of BCP supplementation on SCS and
inflammatory blood markers during a second acute mastitis challenge once BCP supplementation
ceased, as an initial assessment of potential BCP impacts on immune training. We hypothesized
that BCP supplementation would lower the SCS, inflammatory blood markers, and improve the
resolution of mastitis.
21
Materials and Methods
Cows, treatments, and experimental design. All procedures were approved by the
Michigan State University Institutional Animal Care and Use Committee (protocol no.
PROTO202200231). The experiment was conducted at the Michigan State University Dairy
Cattle Teaching and Research Center (Lansing, MI) between August 2022 and November 2022.
Twenty mid or late-lactation Holstein dairy cows (240 ± 60 days in milk [DIM]; 6 primiparous,
14 multiparous), averaging 33 ± 6.9 kg/d of milk yield and free from clinical mastitis, SCS < 4,
were enrolled in a randomized complete block experiment. Using data from a previous
intramammary LPS challenge study (Swartz et al., 2023), we conducted a power analysis based
on body temperature. In the previous study the peak mean body temperature occurred at 5 h post-
challenge, with a standard deviation of 0.34 degrees C. Based on these data, 10 cows per
treatment are sufficient to detect a mean treatment effect of 0.44 °C in body temperature at 5 h
post-challenge with 80% power at α = 0.05. This is sufficiently powerful to detect a meaningful
strategy to reduce LPS-induced inflammation.
The cows were enrolled in two cohorts of 10 cows each, two weeks apart. Cows were
blocked, in blocks of two, by parity, bovine leukemia virus (BLV) status, and DIM, in that order,
at start of challenge, within each cohort. BLV status was used as a blocking factor as it has been
demonstrated that cows which are BLV positive have impaired immune response to stimuli
(Erskine et al., 2011). Treatments were randomly assigned within each block. The experiment
consisted of two treatment groups; 10 cows were assigned to receive the control (CON; no
treatment) and 10 cows were assigned to receive 5 mg/kg of bodyweight (BW) per d of BCP
(#W225207 Sigma-Aldrich). This dose was selected in part due to anti-inflammatory effects of
this dose in mice (Gertsch et al., 2008) and because this is the recommended greatest dose in
22
livestock feed under a European Union approval (https://eur-lex.europa.eu/legal-
content/EN/TXT/HTML/?uri=CELEX:32017R0065).
Cows were housed in a tie-stall barn, milked three times daily (0500, 1300, and 2100 h)
in a milking parlor, and fed a total mixed ration (TMR) once per day (1000 h) for a 10% refusal
rate. Cows had ad libitum access to water. Upon morning feeding (1000 h), BCP treatments were
administered as a top-dress from d 0 until d 42; cows were monitored until d 70. Prior to the first
mastitis challenge, quarter-level milk samples from the right rear (RR) quarter were taken to
screen for an active mastitis case in that quarter. The 5 cows within each treatment group in each
cohort (out of 6) with the lowest quarter-level somatic cell count (SCC) were selected for
mastitis challenge (total n = 10 per treatment). Both CON and BCP groups included 5 BLV-
positive and 5 BLV-negative cows.
Data collection and sample analysis. TMR samples were collected (prior to BCP
administration) every week throughout the experiment and composited at two-week intervals
prior to analysis (Table 1). TMR samples were evaluated for dry matter (DM), crude protein
(CP), starch, ethanol-soluble carbohydrates, neutral detergent fiber (NDF), lignin, crude fat, ash,
and minerals using NIR spectroscopy (Cumberland Valley Analytical Services).
Bodyweight was measured once per week and body condition score (BCS) was assessed
once per week by 3 trained investigators on a 1-5 scale (Wildman et al., 1982). Milk yield and
milk conductivity were measured at each milking in the milking parlor with an electronic
monitoring system (AFIMILK, Kibbutz Afikim, Israel). Composite milk samples (~50 mL) were
collected on d 14, 23, 24, 30, 37, 38, 45, and 52 in a sealed tube with a preservative (bronopol)
and stored at 4°C for milk component (milkfat, protein, lactose) and SCC analyses (Bentely
FTM/FCS, Bentely Instruments Inc.; CentralStar DHI). Energy-corrected milk (ECM) yield was
23
calculated using the formula: ECM = (0.327 × milk kg) + (12.95 × fat kg) + (7.65 × protein kg).
Somatic cell score (SCS) was calculated using the formula: SCS = log₂ (SCC/100,000) + 3 (Ali
and Shook, 1980). Quarter-level milk samples were collected from the RR quarter at the evening
milking (2100 h) on d 24 and 0, 8, 16, or 24 h after each challenge. Samples during the first 24 h
after challenge were diluted 1:10 in PBS for flow cytometric analysis. Quarter level samples
were then taken once daily for the next 6 d following each LPS challenge; these samples were
not diluted in PBS. All quarter-level milk samples were analyzed for SCC as described above.
Body temperature was collected every 10 min from 24 h prior to each LPS challenge
until 72 h after each LPS challenge. The body temperature was collected using a thermometer
(iButton DS1921H; Embedded Data Systems) which was placed on a blank controlled internal
drug release device (CIDR; Zoetis). Prior to insertion of the CIDR, the vulva of the cow was
cleaned with water and disinfected with betadine solution. Then, a lubricant was applied to the
CIDR and vulva then the CIDR containing the iButton inserted into the vagina of each cow.
Blood samples were collected on d 14, 24, 28-34 and d 56-62 after the 2100 h milking
(~2200 h). Blood samples were also collected 8 h and 16 h after each LPS challenge. Blood was
collected by coccygeal venipuncture with tubes containing K 2EDTA; samples were immediately
placed on ice and transported to the lab where they were centrifuged for 15 min at 1,500 × g to
collect the plasma. Two aliquots of plasma were kept at -20°C for later analysis. Plasma was
analyzed for glucose by enzymatic methods (kit #997-03001; Fujifilm, Osaka, Japan), insulin
using a bovine specific ELISA (no. 10–1201–01; Mercodia AB, Uppsala, Sweden), haptoglobin
using a bovine specific ELISA (Hp; kit # HAPT-11; Life Diagnostics, West Chester, PA), LPS
binding protein by ELISA (LBP; cat # CKH113; Cell Scienes, Newburyport, MA), and β-
hydroxybutyrate by enzymatic assay (BHB; kit no. H7587-58; Pointe Scientific Inc., Canton,
24
MI). The inter-assay coefficients of variation (CV) were 5.81, 6.48, 7.22, 5.26, and 5.23 for
glucose, insulin, Hp, LBP and BHB, respectively. Intra-assay CV were 5.17, 5.11, 6.55, 5.02,
and 5.37 5.81, 6.48, 7.22, 5.26, and 5.23 for glucose, insulin, Hp, LBP, and BHB, respectively.
The Mass Spectrometry and Metabolomics Core at Michigan State University conducted
the analysis of BCP in feed and milk using gas chromatography-mass spectrometry. For
quantification in the TMR, approximately 3.0 – 4.5 g of feed (frozen and thawed, not dried) was
transferred into 40 mL amber vials capped with Teflon septa. Samples were loaded onto a
sampling tray set at 40°C and equilibrated for 30 min before headspace was sampled with an
autosampler equipped with a solid phase microextraction (SPME) syringe and fiber (30 mm
divinylbenzene/Carboxen 50 μm polydimethylsiloxane, Milipore-Sigma). The headspace
extraction time was 10 min and volatiles were desorbed at 250°C with splitless mode on an
Agilent 7890B GC with a 7010b triple quadrupole mass spectrometer. Separation was achieved
on an Agilent J&W VF5ms (30 m × 0.25 mm × 0.25 mm; Agilent) using the following
temperature profile: 40°C for 4 min; 20°C min-1 to 250°C; 250°C for 2 min. Ionization employed
70 eV electron ionization and the mass spectrometer was operated in selected ion mode for m/z
93 and 204 for BCP.
Milk samples were prepared by pipetting 500 μL of milk sample, 100 μL 0.05 ng/μL of
tetradecane, and 9.4 mL of Milli-Q water to 40 mL amber vials capped with Teflon septa.
Samples were loaded onto a purge and trap unit (Atomx XYZ). The sample cup was held at 50°C
and volatiles were purged in the sample vials for 11 min with 40 mL/min of nitrogen gas onto a
#9 trap held at room temperature. The trap was heated to 250°C for 2 min and volatiles were
desorbed with a 1:5 pulsed split mode on an 7890A GC with a 5975 single quadrupole mass
spectrometer (Agilent). Separation was achieved on an Agilent J&W VF5ms (30 m × 0.25 mm ×
25
0.25 mm; Agilent) using the following temperature profile: 40°C for 4 min; 20°C min-1 to
250°C; 250°C for 2 min. Ionization employed 70 eV electron ionization and the mass
spectrometer was operated in selected ion mode for m/z 93 and 204 for BCP and m/z 198 for
tetradecane.
Lipopolysaccharide challenges. Lipopolysaccharide (LPS; E. coli O11:B4, Millipore
Sigma, St. Louis, MO) challenges were conducted at the final milking (2100 h) on d 27 and d 55
of the experiment. The challenges were all conducted in the RR quarter of each cow. To conduct
the challenge, cows were milked according to farm protocols. After milking was completed , the
teat end was scrubbed with an alcohol swab to remove bacteria. Then, 5 mL of PBS containing
100 µg of LPS (20 µg/mL) were infused into the RR quarter. The solution was then massaged
upward into the mammary gland. The post-milking procedure was then completed according to
farm protocols.
Statistical analysis. All data were analyzed using linear mixed models (GLIMMIX; SAS
9.4, Cary NC). Dry matter intake (DMI), milk yield, milk composition, and milk component
yields were analyzed using repeated measures mixed linear models for pre-challenge, post-
challenge 1, and post-challenge 2 data. Change in BW and BCS (ΔBW, ΔBCS) were evaluated
as repeated measures and included fixed effects of treatment, time, their interaction, BLV status,
and parity. Random effects included cohort and cow. For ΔBW, ΔBCS, SCS, and body
temperature, the spatial power covariance structure was used due to unequal spacing of
measurements. Normality of residuals was visually appraised. Observations with a Studentized
residual ≥ 4 or ≤ -4 were removed from the data set for each variable and the models were refit if
observations were removed.
26
Quarter-level somatic cell score (SCS; [log2(somatic cell count/100,000) + 3]) was
analyzed as a repeated measure using a compound symmetry covariance structure due to equal
spacing of measurements. The model included the fixed effects of treatment, time post challenge,
and challenge (1st vs. 2nd). All two and three-way interactions were included in the initial model
and removed if P >0.10. For plasma markers, the model used was the same except for the use of
autoregressive covariance structure. Cow was included as a random effect in each model. Model
assumptions were evaluated as described previously.
Body temperature and blood analytes were analyzed as an area under the curve (AUC;
ΔC° × min) using the trapezoidal rule. Baseline body temperatures were calculated by averaging
the temperature of each cow for 12 h prior to LPS infusion. The model included treatment,
challenge (challenge 1 vs. challenge 2) and their interaction. AUC was evaluated as a repeated
measure using the compound symmetry covariance structure. Cow was included as a random
effect in the model.
Statistical significance was declared at P ≤ 0.05 and tendencies at 0.05 < P ≤ 0.10 for
each variable and model that were run.
Results and Discussion
Baseline period & BCP analysis. Prior to LPS challenge, no treatment effects on DMI
were observed (Table 2), similar to results reported by Oliveira (2018) using BCP as an oral
supplement in mice models. Treatment did not significantly affect milk yield or energy-corrected
milk (ECM; Table 2). Furthermore, the ΔBW and ΔBCS were not affected by treatment (Table
5), consistent with both the lack of DMI differences and findings in mice (Oliveira et al., 2018).
BCP was detected in purified samples used for treatment (95% BCP according to the LC-MS
analysis), consistent with specifications from the supplier, but we found no evidence of BCP in
27
milk or any basal presence in the TMR. Milk and TMR samples were stored in a -20°C freezer
for 6 months, then thawed prior to analysis; storage and handling of the milk and TMR samples
may have affected our ability to detect BCP due to its volatile nature (Gertsch et al., 2008). The
volatile nature of BCP also raises the possibility of all of it evaporating prior to ingestion thus
explaining our inability to detect it in the milk and TMR.
Prior to LPS challenges, our findings suggest that BCP supplementation had no apparent
adverse or beneficial effects on late-lactation dairy cattle. This could possibly be due to rumen
degradation of BCP. Poulopoulou and Hadjigeorgiou (2021) evaluated terpene degradation in
rumen fluid using an ovine model and found that BCP degradation rate was greatest after 1 week
of oral supplementation (approximately 4.3% per hour, dosed at 1 g). These baseline period
results, paired with our inability to detect BCP in milk collected from treated cows, suggests no
risks of meaningful quantities of BCP getting into the food chain, thus setting the stage for
further research on BCP supplementation in dairy cattle.
One potential explanation for the inability to detect BCP in milk samples during this
study is BCP’s low oral bioavailability and high sensitivity to oxidation when exposed to oxygen
and light (Liu et al., 2013; Di Sotto et al., 2018). Bioavailability of a molecule depends on its
chemical and physical properties, and typically reflects water solubility and membrane
permeability (Di Sotto et al., 2018). It is important to note that BCP has high lipophilicity, which
subsequently limits its bioavailability and absorption. Assuming the BCP is not degraded in the
rumen, it would be taken up in the small intestine (Di Sotto et al., 2018). In a human study by
Mödinger et al. (2022) using similar dosage of 100 mg per subject, using a self-emulsifying drug
delivery system to orally supplement BCP significantly increased the BCP AUC0-12h and AUC0-
24h concentrations by 2.2-fold and 2.0-fold, respectively. They also found a 3.6-fold increase in
28
maximum plasma concentration and time to maximum blood concentration was 1.43 vs. 3.04 h
for BCP delivered as a neat oil. Therefore, the form of supplementation in this experiment may
have affected its uptake. Little information is available on rumen degradation of BCP other than
results from Poulopoulou and Hadjigeorgiou (2021) using a sheep model, who found that rumen
degradation of BCP was approximately 13%/h on average for the first week of supplementation
and then dropped to approximately 4.3%/h in the following week. Further work should be done
to evaluate the degradation of BCP using a bovine model, as well as determining the efficacy of
formulating BCP to self-emulsify through oral and abomasal supplementation.
LPS challenge 1. During an intramammary LPS challenge, dairy cattle experience a drop
in DMI and milk production while also having an increase in body temperature and somatic cell
count in milk (Johnzon et al., 2018). Temporal patterns in this study were similar to those
reported previously, with a noticeable rise in body temperature beginning roughly 2 h post-
challenge, peaking (~41°C) at 6 h post-challenge, and returning to baseline 12 h post-challenge
(Figure 1). There was no detectable impact of treatment on these body temperature patterns.
After challenge, DMI and milk production were not significantly affected by BCP
supplementation (Table 2). On the other hand, BCP supplementation significantly reduced SCS
(Figure 3) on d 52 of the study (10 days after BCP supplementation ended), potentially pointing
to more complete resolution of challenge-induced inflammation in the mammary gland.
Treatment did not affect plasma glucose, insulin, BHB or lipopolysaccharide binding protein
(LBP) concentrations in the 16 h after the first LPS challenge (Table 3). However, BCP
supplementation significantly lowered haptoglobin concentrations (Table 3) over the 16 h post-
challenge.
29
The reduction in plasma haptoglobin and the greater drop in SCS 10 d after challenge
may be in part due to BCP’s ability to decrease the expression of pro-inflammatory signals,
allowing for a more complete resolution (Aly et al., 2020; Johnzon et al., 2018). When looking at
the results following the first of the LPS challenge, we did not observe sufficient evidence to
support our hypothesis that BCP would lessen the inflammatory response. A recent study by
Jermann et al. (2023) varying the dietary supply of macronutrients found no difference in the
systemic inflammatory response to an intramammary LPS injection based on macronutrient
profile, but they did observe a significant increase in acute phase proteins (APPs) in milk before
APP changes were detectable in plasma. This discovery raises the question of whether
inflammatory mediators from the challenged quarter cause the systemic reactions observed, or if
LPS itself is entering the bloodstream. Haptoglobin is a positive APP synthesized by the liver; it
is found in low concentrations in healthy animals but is quickly released into the bloodstream
during an infection. It is a protein with antioxidant, antimicrobial, and anti-inflammatory
properties through its ability to scavenge free hemoglobin and bind to neutrophil integrins
(Gulhar et al., 2023). It results in the release of other anti-inflammatory mediators such as IL-10
(Quaye, 2008; Ceciliani et al., 2012). While we didn’t detect any improvements in feed intake or
milk yield in this study, lower concentrations of plasma haptoglobin suggests that cows
experienced less inflammation and hepatic stress as a result of BCP supplementation. The lower
SCS observed at 24 d post-challenge in cows previously supplemented with BCP could also be
explained by the anti-inflammatory effects of BCP potentially blunting the severity of the APP
response in the affected quarter. The decrease in SCS and haptoglobin that was observed
provides evidence that further research needs to be conducted looking at supplementing BCP to
dairy cattle in a challenge setting. However, without any significant changes in any other acute
30
phase proteins, body temperature, or milk production, it is unclear if inflammation was mitigated
during this challenge as a result of BCP supplementation.
LPS Challenge 2. Repeated exposure to the same pathogen or pathogen-associated
molecule can alter the immune system through innate training, resulting in the host having either
a heighted or a suppressed innate immune response (Byrne et al., 2020). BCP treatment
administration ended 2 weeks after the initial LPS challenge and 2 weeks prior to the second LPS
challenge, to evaluate whether BCP supplementation influenced trained immunity. The 2 weeks
prior to the second LPS challenge was to allow for BCP to leave the guy/body, however since we
didn’t collect adipose samples there is a possibility that BCP may be stored in adipocytes.
In accordance with our hypothesis, BCP treatment appeared to have an effect on response
to repeated LPS challenge. BCP supplementation resulted in a significantly greater quarter-level
SCS score 16 hours after the second LPS challenge (Figure 4); there was no significant effect at
any other time point. This could be due to increased sensitivity after the first LPS challenge
(Byrne et al., 2020), but more work needs to be conducted into nutritional impacts on innate
training to explain this response. After the second LPS challenge no treatment effects were
observed for plasma glucose, insulin, haptoglobin, BHB, or LBP (Table 3). BCP
supplementation has not been previously studied in cattle, so while the lack of difference in DMI
and BW changes are supported by murine models, further research needs to be conducted to
elucidate BCP effects on performance responses in dairy cattle.
We expected to see a lesser acute phase response when comparing challenge 2 to
challenge 1, as demonstrated in other studies looking at innate training (Ifrim et al., 2014;
Sullivan et al., 2023). For haptoglobin, there was indeed a significant reduction in plasma AUC
for the second challenge compared to the first (Table 4). However, the body temperature
31
response for the second LPS challenge was similar to that of the first challenge (Figures 1 & 2).
When comparing the AUC for other plasma metabolites between challenges, we expected to see
a lower AUC value for the second challenge but instead glucose, insulin, BHB, and LBP were
not significantly different. Our findings when comparing between challenges was unexpected as
other groups that have looked at repeated LPS challenges observed a lesser fever response due to
innate training (Petzl et al., 2012).
In contrast to other plasma analytes, we observed a lower concentration of plasma
haptoglobin after challenge 2 compared to challenge 1. This lesser concentration in the second
challenge points to the possibility of tolerance to LPS following the first challenge, but this idea
conflicts with the increased SCS response 16 hours after challenge, pointing to increased
sensitivity as opposed to the tolerance observed with the haptoglobin AUC. This increased
sensitivity in the mammary gland may be due to the anti-inflammatory effects of BCP that were
present during the first LPS challenge. It is possible that BCP limited the local inflammatory tone
of cows during the first challenge, “training” the intramammary immune cells in BCP-treated
cows compared to CON cows and thus leading to, increased immune cell migration and a higher
SCS in the BCP cows during the second challenge. This raises a question of whether an
observable difference in the inflammatory response would be expected, potentially impacting
body temperature, feed intake, and milk responses, if this altered immune training was monitored
while BCP supplementation was maintained. To test this, future studies could be conducted
looking at repeated LPS challenges with BCP being supplied through both LPS challenges.
While these findings are interesting, without other evidence of altered systemic responses
– such as a lower body temperature or SCS – we are unable to clearly state that we successfully
trained the innate immune system through repeated LPS challenges.
32
Conclusions
Supplementation of BCP to late lactation dairy cattle did not cause any detrimental
effects to production or homeostasis during a basal period. When looking at BCP
supplementation during the first LPS challenge, a decrease in SCS and a reduction in
haptoglobin concentrations suggest that BCP could help mitigate the inflammatory responses to
an intramammary LPS challenge. During the second LPS challenge, results suggest that BCP
supplementation did not have an impact on innate training except for when looking at plasma
haptoglobin concentrations compared to challenge 1. One measurement that was not collected in
this study but would be advisable for future research is to confirm BCP supplementation was
effective by testing its plasma concentration. The few significant results observed could be due
to BCP’s low bioavailability and uptake, which we are unable to determine with this experiment.
We conclude that BCP supplementation appears to be safe at a rate of 5 mg/kg BW without
disrupting the function of late lactation dairy cattle, however, we are unable to conclude that it is
a useful treatment for inflammation. Although BCP treatment significantly decreased SCC and
haptoglobin concentrations at particular timepoints after intramammary LPS challenge, future
research needs to be conducted to fully elucidate the function of BCP as an inflammatory
modulator in lactating dairy cattle.
33
CHAPTER 3:
IMPLICATIONS AND CONCLUSIONS
34
Implications and Conclusions
The average lactating cow replacement rate in the U.S. dairy industry is 35%, while cows
are often replaced due to health events, this replacement rate is far from optimal in terms of
economic, social, or environmental sustainability (Murat Tatar et al., 2017; Overton and
Dhuyvetter, 2020). Due to societal pressure, a veterinary feed directive (VFD) was established in
2017 to reduce the use of antibiotics in livestock production. To help improve the resilience of
cows to pathogens, further research needs to be done to investigate naturally occurring compounds
that may help decrease the need for antibiotic use. By studying compounds such as BCP, we may
better understand ways in which nutrition can improve the immune function of dairy cattle.
The goal of this work is to access how BCP supplementation changes the inflammatory
response in late lactation dairy cattle experiencing repeated intramammary LPS challenges. The
study evaluated the effect of BCP supplementation on the inflammatory responses from late
lactation Holstein cows as well as any carryover effects of BCP supplementation on a subsequent
LPS challenge. Parameters such as BHB, glucose, haptoglobin, insulin, LBP, and body
temperature were evaluated to measure the inflammatory response. BCP supplementation
significantly reduced haptoglobin during the first LPS challenge and led to a significant decrease
in SCC 10 days after supplementation ended, but had no effect on DMI, milk or component
yields, or any of the other analytes measured. BCP supplementation resulted in a higher peak for
SCC at 16 h after the second challenge, but similarly had no impact on DMI, milk or component
yields, or any of the other analytes measured. When comparing the first challenge to the second
challenge there was a tendency for cows to have lower levels of haptoglobin during the second
challenge. Considering the anti-inflammatory effects of BCP it may have lowered the
haptoglobin levels following the first challenge, while trained immunity may be the reason for
35
the lower levels of haptoglobin when comparing the two challenges, as well as the higher peak
for SCC observed in the second LPS challenge.
This study concludes that further work should be done to determine if BCP
supplementation would alter the inflammatory response upon repeated LPS challenges. Work
investigating BCP supplementation for both of the LPS challenges is warranted. Evaluation of
BCP supplementation on the inflammatory response will potentially help the current problem of
susceptibility to some infectious diseases further lessening the need of antibiotics. With this
study, we conclude that BCP affects haptoglobin and SCC of dairy cows experiencing an
intramammary LPS challenge.
36
BIBLIOGRAPHY
Abebe, R., H. Hatiya, M. Abera, B. Megersa, and K. Asmare. 2016. Bovine mastitis: Prevalence,
risk factors and isolation of Staphylococcus aureus in dairy herds at Hawassa milk shed, South
Ethiopia. BMC Vet Res 12. Doi:10.1186/s12917-016-0905-3.
Abuelo, A., J. Hernández, J.L. Benedito, and C. Castillo. 2015. The importance of the oxidative
status of dairy cattle in the periparturient period: Revisiting antioxidant supplementation. J Anim
Physiol Anim Nutr (Berl) 99:1003–1016. Doi:10.1111/jpn.12273.
Adcock, I.M., and G. Caramori. 2009. Transcription Factors. Asthma and COPD: Basic
Mechanisms and Clinical Management 373–380. Doi:10.1016/B978-0-12-374001-4.00031-6.
Ali, A.K.A., and G.E. Shook. 1980. An Optimum Transformation for Somatic Cell
Concentration in Milk. J Dairy Sci 63:487–490. Doi:10.3168/jds.S0022-0302(80)82959-6.
Aly, E., M.A. Khajah, and W. Masocha. 2020. Β-caryophyllene, a CB2-receptor-selective
phytocannabinoid, suppresses mechanical allodynia in a mouse model of antiretroviral-induced
neuropathic pain. Molecules 25. Doi:10.3390/molecules25010106.
Anderson KL, Hunt E. Anti-inflammatory therapy in acute endotoxin-induced bovine mastitis.
Vet Res Commun. 1989;13(1):17-26. doi: 10.1007/BF00366848. PMID: 2672555.Badinga, L.,
and C. Caldari-Torres. Omega-3 Fatty Acids Control Immune Stress in Dairy Cattle 1.
Barragan AA, Bas S, Hovingh E, Byler L. Effects of postpartum acetylsalicylic acid on uterine
diseases and reproductive performance in dairy cattle. JDS Commun. 2021 Jan 22;2(2):67-72.
doi: 10.3168/jdsc.2020-0047. PMID: 36338778; PMCID: PMC9623653.Basu S, Dittel BN.
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and
disease. Immunol Res. 2011 Oct;51(1):26-38. doi: 10.1007/s12026-011-8210-5. PMID:
21626285; PMCID: PMC4624216.Bertoni, G., E. Trevisi, and F. Piccioli-Cappelli. 2004.
Effects of acetyl-salicylate used in post-calving of dairy cows. Vet Res Commun 28:217–219.
Doi:10.1023/B:VERC.0000045410.86004.03.
Bolognini, D., B. Costa, S. Maione, F. Comelli, P. Marini, V. Di Marzo, D. Parolaro, R.A. Ross,
L.A. Gauson, M.G. Cascio, and R.G. Pertwee. 2010. The plant cannabinoid Δ 9-
tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J
Pharmacol 160:677–687. Doi:10.1111/j.1476-5381.2010.00756.x.
Bradford, B. 2020. Transition Cows-How Fatty Acids Affect Immunity, Production and Health.
Gainesville.
37
Bradford, B.J., K. Yuan, J.K. Farney, L.K. Mamedova, and A.J. Carpenter. 2015. Invited review:
Inflammation during the transition to lactation: New adventures with an old flame. J Dairy Sci
98:6631–6650. Doi:10.3168/jds.2015-9683.
Breen, J. 2017. The importance of non-steroidal anti-inflammatory drugs (NSAIDs) in mastitis
therapeutics. Livestock 22:182–185. Doi:10.12968/live.2017.22.4.182.
Byrne, K.A., C.L. Loving, and J.L. McGill. 2020. Innate Immunomodulation in Food Animals:
Evidence for Trained Immunity?. Front Immunol 11. Doi:10.3389/fimmu.2020.01099.
Cain, D.W., and J.A. Cidlowski. 2017. Immune regulation by glucocorticoids. Nat Rev Immunol
17:233–247. Doi:10.1038/nri.2017.1.
Calder PC. Long-chain fatty acids and inflammation. Proc Nutr Soc. 2012 May;71(2):284-9. doi:
10.1017/S0029665112000067. Epub 2012 Feb 28. PMID: 22369781.
Calder PC. Feeding the immune system. Proc Nutr Soc. 2013 Aug;72(3):299-309. doi:
10.1017/S0029665113001286. Epub 2013 May 21. PMID: 23688939.
Capozzi, A., D. Caissutti, V. Mattei, F. Gado, S. Martellucci, A. Longo, S. Recalchi, V.
Manganelli, G. Riitano, T. Garofalo, M. Sorice, C. Manera, and R. Misasi. 2022. Anti-
inflammatory activity of a cb2 selective cannabinoid receptor agonist: Signaling and cytokines
release in blood mononuclear cells. Molecules 27. Doi:10.3390/molecules27010064.
Carrasco, F.R., G. Schmidt, A.L. Romero, J.L. Sartoretto, S.M. Caparroz-Assef, C.A. Bersani-
Amado, and R.K.N. Cuman. 2009. Immunomodulatory activity of Zingiber officinale
Roscoe, Salvia officinalis L. and Syzygium aromaticum L. essential oils:
evidence for humor- and cell-mediated responses. Journal of Pharmacy and Pharmacology
61:961–967. Doi:10.1211/jpp/61.07.0017.
Ceciliani, F., J.J. Ceron, P.D. Eckersall, and H. Sauerwein. 2012. Acute phase proteins in
ruminants. J Proteomics 75:4207–4231. Doi:10.1016/j.jprot.2012.04.004.
Cha, E., D. Bar, J.A. Hertl, L.W. Tauer, G. Bennett, R.N. González, Y.H. Schukken, F.L.
Welcome, and Y.T. Gröhn. 2011. The cost and management of different types of clinical mastitis
in dairy cows estimated by dynamic programming. J Dairy Sci 94:4476–4487.
Doi:10.3168/jds.2010-4123.
Chandrasekharan, N., Simmons, D.L. The cyclooxygenases. Genome Biol 5, 241 (2004).
https://doi.org/10.1186/gb-2004-5-9-241Chaplin, D.D. 2010. Overview of the immune response.
Journal of Allergy and Clinical Immunology 125. Doi:10.1016/j.jaci.2009.12.980.
38
Chayasirisobhon, S. 2021. Mechanisms of Action and Pharmacokinetics of Cannabis.
Permanente Journal 25. Doi:10.7812/TPP/19.200.
Chen, J.H., and C.-T. Ho. 1997. Antioxidant Activities of Caffeic Acid and Its Related
Hydroxycinnamic Acid Compounds.
Cheng, W.N., and S.G. Han. 2020. Bovine mastitis: risk factors, therapeutic strategies, and
alternative treatments — A review. Asian-Australas J Anim Sci 33:1699–1713.
Doi:10.5713/ajas.20.0156.
Chiurchiù, V., M. Lanuti, M. De Bardi, L. Battistini, and M. Maccarrone. 2015. The differential
characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in
monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 27:153–
160. Doi:10.1093/intimm/dxu097.
Contreras, G.A., S.A. Mattmiller, W. Raphael, J.C. Gandy, and L.M. Sordillo. 2012. Enhanced
n-3 phospholipid content reduces inflammatory responses in bovine endothelial cells. J Dairy Sci
95:7137–7150. Doi:10.3168/jds.2012-5729.
Correa, F., F. Docagne, L. Mestre, D. Clemente, M. Hernangómez, F. Loría, and C. Guaza. 2009.
A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12
and IL-23 in microglial cells. Biochem Pharmacol 77:86–100. Doi:10.1016/j.bcp.2008.09.014.
Erskine, R.J., P.C. Bartlett, K.M. Sabo, and L.M. Sordillo. 2011. Bovine leukemia virus infection
in dairy cattle: Effect on serological response to immunization against J5 Escherichia coli
Bacterin. Vet Med Int 2011. Doi:10.4061/2011/915747.
Finch, J.M., and R.J. Turner. 1996. Effects of selenium and vitamin E on the immune responses
of domestic animals.
Francomano, F., A. Caruso, A. Barbarossa, A. Fazio, C. La Torre, J. Ceramella, R. Mallamaci,
C. Saturnino, D. Iacopetta, and M.S. Sinicropi. 2019. Β-caryophyllene: A sesquiterpene with
countless biological properties. Applied Sciences (Switzerland) 9. Doi:10.3390/app9245420.
Fujisawa, S., T. Atsumi, Y. Kadoma, and H. Sakagami. 2002. Antioxidant and prooxidant action
of eugenol-related compounds and their cytotoxicity.
Garavaglia, L., S. Galletti, and D. Tedesco. 2015. Silymarin and lycopene administration in
periparturient dairy cows: effects on milk production and oxidative status. N Z Vet J 63:313–
318. Doi:10.1080/00480169.2015.1047911.
39
Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak,
M., & Zimmer, A. (2008). Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci
105:9099– 9104.
Gertsch, J., R.G. Pertwee, and V. Di Marzo. 2010. Phytocannabinoids beyond the Cannabis plant
- Do they exist? Br J Pharmacol 160:523–529. doi:10.1111/j.1476-5381.2010.00745.x.
González, R., I. Ballester, R. López-Posadas, M.D. Suárez, A. Zarzuelo, O. Martínez-Augustin,
and F. Sánchez de Medina. 2011. Effects of flavonoids and other polyphenols on inflammation.
Crit Rev Food Sci Nutr 51:331–362. doi:10.1080/10408390903584094.
Greco, L.F., J.T.N. Neto, A. Pedrico, R.A. Ferrazza, F.S. Lima, R.S. Bisinotto, N. Martinez, M.
Garcia, E.S. Ribeiro, G.C. Gomes, J.H. Shin, M.A. Ballou, W.W. Thatcher, C.R. Staples, and
J.E.P. Santos. 2015. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on performance
and inflammatory responses to a lipopolysaccharide challenge in lactating Holstein cows. J Dairy
Sci 98:602–617. doi:10.3168/jds.2014-8805.
Guerra-Maupome, M., D.X. Vang, and J.L. McGill. 2019. Aerosol vaccination with Bacille
Calmette-Guerin induces a trained innate immune phenotype in calves. PLoS One 14.
doi:10.1371/journal.pone.0212751.
Gulhar, R., M.A. Ashraf, and I. Jialal. 2023. Physiology, Acute Phase Reactants.
Harris, S.L., D.A. Clark, and P.J. Laboyrie. 1998. Birdsfoot trefoil-an alternative legume for
New Zealand dairy pastures.
Hashemzadeh-Cigari, F., M. Khorvash, G.R. Ghorbani, M. Kadivar, A. Riasi, and Q. Zebeli.
2014. Effects of supplementation with a phytobiotics-rich herbal mixture on performance, udder
health, and metabolic status of Holstein cows with various levels of milk somatic cell counts. J
Dairy Sci 97:7487–7497. doi:10.3168/jds.2014-7989.
Hoffmann, A., and D. Baltimore. 2006. Circuitry of nuclear factor κB signaling. Immunol Rev
210:171–186. doi:10.1111/j.0105-2896.2006.00375.x.
Hogan, J., and K.L. Smith. 2003. Coliform mastitis. Vet Res 34:507–519.
doi:10.1051/vetres:2003022.
Ifrim, D.C., J. Quintin, L.A.B. Joosten, C. Jacobs, T. Jansen, L. Jacobs, N.A.R. Gow, D.L.
Williams, J.W.M. Van Der Meer, and M.G. Netea. 2014. Trained immunity or tolerance:
Opposing functional programs induced in human monocytes after engagement of various pattern
recognition receptors. Clinical and Vaccine Immunology 21:534–545. doi:10.1128/CVI.00688-
13.
40
Iribarren, P., H. Cui, Y. Le, G. Ying, X. Zhang, W. Gong, and J.M. Wang. 2003. IL-4 Down-
Regulates Lipopolysaccharide-Induced Formyl Peptide Receptor 2 in Murine Microglial Cells by
Inhibiting the Activation of Mitogen-Activated Protein Kinases 1,2.
Jermann, P.M., L.A. Wagner, D. Fritsche, J.J. Gross, O. Wellnitz, and R.M. Bruckmaier. 2023.
Acute phase reaction to LPS induced mastitis in early lactation dairy cows fed nitrogenic,
glucogenic or lipogenic diets. J Dairy Sci. doi:10.3168/jds.2023-23582.
Johnzon, C.F., J. Dahlberg, A.M. Gustafson, I. Waern, A.A. Moazzami, K. Östensson, and G.
Pejler. 2018. The effect of lipopolysaccharide-induced experimental bovine mastitis on clinical
parameters, inflammatory markers, and the metabolome: A kinetic approach. Front Immunol 9.
doi:10.3389/fimmu.2018.01487.
Jürg Gertsch, C., and J. Gertsch. 2017. Cannabimimetic phytochemicals in the diet-an
evolutionary link to food selection and metabolic stress adaptation? * LINKED ARTICLES. Br J
Pharmacol 174:1464–1483. doi:10.1111/bph.v174.11/issuetoc.
Klauke, A.L., I. Racz, B. Pradier, A. Markert, A.M. Zimmer, J. Gertsch, and A. Zimmer. 2014.
The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic
effects in mouse models of inflammatory and neuropathic pain. European
Neuropsychopharmacology 24:608–620. doi:10.1016/j.euroneuro.2013.10.008.
Klein, T.W. 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev
Immunol 5:400–411. doi:10.1038/nri1602.
Ku-Vera, J.C., R. Jiménez-Ocampo, S.S. Valencia-Salazar, M.D. Montoya-Flores, I.C. Molina-
Botero, J. Arango, C.A. Gómez-Bravo, C.F. Aguilar-Pérez, and F.J. Solorio-Sánchez. 2020. Role
of Secondary Plant Metabolites on Enteric Methane Mitigation in Ruminants. Front Vet Sci 7.
doi:10.3389/fvets.2020.00584.
Lee, J.Y., L. Zhao, and D.H. Hwang. 2010. Modulation of pattern recognition receptor-mediated
inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev 68:38–61.
doi:10.1111/j.1753-4887.2009.00259.x.
Liu, H., G. Yang, Y. Tang, D. Cao, T. Qi, Y. Qi, and G. Fan. 2013. Physicochemical
characterization and pharmacokinetics evaluation of β-caryophyllene/β-cyclodextrin inclusion
complex. Int J Pharm 450:304–310. doi:10.1016/j.ijpharm.2013.04.013.
Lohuis, J.A.C.M., W. Van Leeuwen, J.H.M. Verheijden, A.S.J.P.A.M. Van Miert, and A. Brand.
1988. Effect of Dexamethasone on Experimental Escherichia coli Mastitis in the Cow. J Dairy
Sci 71:2782–2789. doi:10.3168/jds.S0022-0302(88)79872-0.
41
Mattiuzzo, E., A. Faggian, R. Venerando, A. Benetti, E. Belluzzi, G. Abatangelo, P. Ruggieri,
and P. Brun. 2021. In vitro effects of low doses of β-Caryophyllene, ascorbic acid and D-
Glucosamine on human chondrocyte viability and inflammation. Pharmaceuticals 14.
doi:10.3390/ph14030286.
Medzhitov, R. 2008. Origin and physiological roles of inflammation. Nature 454:428–435.
doi:10.1038/nature07201.
Middleton, E., C. Kandaswami, and T.C. Theoharides. 2000. The Effects of Plant Flavonoids on
Mammalian Cells: Implications for Inflammation, Heart Disease, and Cancer.
Miller, J.K., E. Brzezinska-Slebodzinska, and F.C. Madsen. 1993. Oxidative Stress,
Antioxidants, and Animal Function. J Dairy Sci 76:2812–2823. doi:10.3168/jds.S0022-
0302(93)77620-1.
Miranda, J., A. Lasa, L. Aguirre, A. Fernandez-Quintela, I. Milton, and M.P. Portillo. 2014.
Potential Application of Non-flavonoid Phenolics in Diabetes: Antiinflammatory Effects. Curr
Med Chem 22:112–131. doi:10.2174/0929867321666140815123507.
Mödinger, Y., K. Knaub, T. Dharsono, R. Wacker, R. Meyrat, M.H. Land, A.L. Petraglia, and C.
Schön. 2022. Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the
VESIsorb® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System
(SEDDS). Molecules 27. doi:10.3390/molecules27092860.
Mogensen, T.H. 2009. Pathogen recognition and inflammatory signaling in innate immune
defenses. Clin Microbiol Rev 22:240–273. doi:10.1128/CMR.00046-08.
Morkoç, A.C., W.L. Hurley, H.L. Whitmore, and B.K. Gustafsson. 1993. Bovine Acute Mastitis:
Effects of Intravenous Sodium Salicylate on Endotoxin-Induced Intramammary Inflammation. J
Dairy Sci 76:2579–2588. doi:10.3168/jds.S0022-0302(93)77592-X.
Murat Tatar, A., D. Şireli, and M. Tutkun. 2017. REASONS FOR CULLING AND
REPLACEMENT RATE IN DAIRY CATTLE Animal Mechanization View project Structural
Analysis of Dairy enterprises in Diyarbakır Province/Turkey View project.
Netea MG. Training innate immunity: the changing concept of immunological memory in innate
host defence. Eur J Clin Invest. 2013 Aug;43(8):881-4. doi: 10.1111/eci.12132. PMID:
23869409.
Newby, N.C., K.E. Leslie, H.D.P. Dingwell, D.F. Kelton, D.M. Weary, L. Neuder, S.T. Millman,
and T.F. Duffield. 2017. The effects of periparturient administration of flunixin meglumine on
the health and production of dairy cattle. J Dairy Sci 100:582–587. doi:10.3168/jds.2016-11747.
42
Newton, K., and V.M. Dixit. 2012. Signaling in innate immunity and inflammation. Cold Spring
Harb Perspect Biol 4. doi:10.1101/cshperspect.a006049.
Ogala, H., A. Shitandi, and J. Nanua. 2007. Effect of mastitis on raw milk compositional quality.
Journal of Veterinary Science 8:237–242.
Olagaray, K.E., and B.J. Bradford. 2019. Plant flavonoids to improve productivity of ruminants –
A review. Anim Feed Sci Technol 251:21–36. doi:10.1016/j.anifeedsci.2019.02.004.
Oliveira, G.L. da S., K.C. Machado, K.C. Machado, A.P. dos S.C.L. da Silva, C.M. Feitosa, and
F.R. de Castro Almeida. 2018. Non-clinical toxicity of β-caryophyllene, a dietary cannabinoid:
Absence of adverse effects in female Swiss mice. Regulatory Toxicology and Pharmacology
92:338–346. doi:10.1016/j.yrtph.2017.12.013.
Overton, M.W., and K.C. Dhuyvetter. 2020. Symposium review: An abundance of replacement
heifers: What is the economic impact of raising more than are needed?. J Dairy Sci 103:3828–
3837. doi:10.3168/jds.2019-17143.
Pertwee, R.G. 2006. Cannabinoid pharmacology: The first 66 years. Br J Pharmacol 147.
doi:10.1038/sj.bjp.0706406.
Pertwee, R.G., and R.A. Ross. 2002a. Cannabinoid receptors and their ligands.
Pertwee, R.G., and R.A. Ross. 2002b. Cannabinoid receptors and their ligands.
Petzl, W., J. Günther, T. Pfister, C. Sauter-Louis, L. Goetze, S. Von Aulock, A. Hafner-Marx,
H.J. Schuberth, H.M. Seyfert, and H. Zerbe. 2012. Lipopolysaccharide pretreatment of the udder
protects against experimental Escherichia coli mastitis. Innate Immun 18:467–477.
doi:10.1177/1753425911422407.
Picciolo, G., G. Pallio, D. Altavilla, M. Vaccaro, G. Oteri, N. Irrera, and F. Squadrito. 2020. β-
Caryophyllene reduces the inflammatory phenotype of periodontal cells by targeting CB2
receptors. Biomedicines 8. doi:10.3390/BIOMEDICINES8060164.
Poulopoulou, I., and I. Hadjigeorgiou. 2021. Evaluation of Terpenes’ Degradation Rates by
Rumen Fluid of Adapted and Non-adapted Animals. Nat Prod Bioprospect 11:307–313.
doi:10.1007/s13659-020-00289-3.
Quaye, I.K. 2008. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 102:735–
742. doi:10.1016/j.trstmh.2008.04.010.
Rahaman, O., and D. Ganguly. 2021. Endocannabinoids in immune regulation and
immunopathologies. Immunology 164:242–252. doi:10.1111/imm.13378.
43
Rhen, T., and J.A. Cidlowski. 2005. Antiinflammatory Action of Glucocorticoids-New
Mechanisms for Old Drugs.
Roth, J.A. 1982. Effect of glucocorticoids on the bovine immune system Pathogenesis of
Mycoplasma hyopneumoniae View project.
Scandiffio, R., F. Geddo, E. Cottone, G. Querio, S. Antoniotti, M. Pia Gallo, M.E. Maffei, and P.
Bovolin. 2020. Protective effects of (E)-β-caryophyllene (bcp) in chronic inflammation.
Nutrients 12:1–24. doi:10.3390/nu12113273.
Schottelius, A.J.G., M.W. Mayo, R.B. Sartor, and A.S. Baldwin. 1999. Interleukin-10 Signaling
Blocks Inhibitor of B Kinase Activity and Nuclear Factor B DNA Binding*.
Serhan, C.N. 2009. Systems approach to inflammation resolution: Identification of novel anti-
inflammatory and pro-resolving mediators. Journal of Thrombosis and Haemostasis 7:44–48.
doi:10.1111/j.1538-7836.2009.03396.x.
Shpigel, N.Y., M. Wlnkler, A. Saran, and G. Ziv. 1994. Anti-inflammatory ketoprofen in the
treatment of field cases of bovine mastitis.
Sinz, S., S. Marquardt, C.R. Soliva, U. Braun, A. Liesegang, and M. Kreuzer. 2019. Phenolic
plant extracts are additive in their effects against in vitro ruminal methane and ammonia
formation. Asian-Australas J Anim Sci 32:966–976. doi:10.5713/ajas.18.0665.
Smith, G., J. Davis, L. Tell, A. Webb, and J. Riviere. 2008. Extralabel use of nonsteroidal anti-
inflammatory drugs in cattle. American Veterinary Medical Association 232:697–701.
Smith, K.L., D.A. Todhunter, and P.S. Schoenberger. 1985. Environmental Mastitis: Cause,
Prevalence, Prevention. J Dairy Sci 68:1531–1553. doi:10.3168/jds.S0022-0302(85)80993-0.
Soltan, M.A. 2010. Effect of dietary chromium supplementation on productive and reproductive
performance of early lactating dairy cows under heat stress. J Anim Physiol Anim Nutr (Berl)
94:264–272. doi:10.1111/j.1439-0396.2008.00913.x.
Soltan, Y.A., P.E. Simitzis, N. Zhang, M. Besharati, and A. Lara-Bueno. 2023. Meta-analysis of
flavonoids use into beef and dairy cattle diet: Performance, antioxidant status, ruminal
fermentation, meat quality, and milk composition.
Sordillo, L.M. 2016. Nutritional strategies to optimize dairy cattle immunity. J Dairy Sci
99:4967–4982. doi:10.3168/jds.2015-10354.
Sordillo, L.M. 2018. Symposium review: Oxylipids and the regulation of bovine mammary
inflammatory responses1. J Dairy Sci 101:5629–5641. doi:10.3168/jds.2017-13855.
44
Sordillo, L.M., and S.L. Aitken. 2009. Impact of oxidative stress on the health and immune
function of dairy cattle. Vet Immunol Immunopathol 128:104–109.
doi:10.1016/j.vetimm.2008.10.305.
Sordillo, L.M., and W. Raphael. 2013. Significance of metabolic stress, lipid mobilization, and
inflammation on transition cow disorders. Veterinary Clinics of North America - Food Animal
Practice 29:267–278. doi:10.1016/j.cvfa.2013.03.002.
Sordillo LM, Streicher KL. Mammary gland immunity and mastitis susceptibility. J Mammary
Gland Biol Neoplasia. 2002 Apr;7(2):135-46. doi: 10.1023/a:1020347818725. PMID: 12463736.
Swartz, T. H., B. J. Bradford, L. K. Mamedova, and K. A. Estes. 2023. Effects of dietary rumen-
protected choline supplementation to periparturient dairy cattle on inflammation, metabolism,
and performance during an intramammary lipopolysaccharide challenge. J Dairy Sci. 106:8561–
82. https://doi.org/10.3168/jds.2023-23259.
Di Sotto, A., P. Paolicelli, M. Nardoni, L. Abete, S. Garzoli, S. Di Giacomo, G. Mazzanti, M.A.
Casadei, and S. Petralito. 2018. SPC liposomes as possible delivery systems for improving
bioavailability of the natural sesquiterpene β-caryophyllene: Lamellarity and drug-loading as key
features for a rational drug delivery design. Pharmaceutics 10.
doi:10.3390/pharmaceutics10040274.
Sullivan, T., A. Sharma, K. Lamers, B.A. Mallard, A. Cánovas, and N.A. Karrow. 2023.
Immunotolerance of dairy heifers in response to repeated exposure to bacterial
lipopolysaccharide endotoxin. Vet Immunol Immunopathol 259.
doi:10.1016/j.vetimm.2023.110579.
Sung, M.H., N. Li, Q. Lao, R.A. Gottschalk, G.L. Hager, and I.D.C. Fraser. 2014. Switching of
the relative dominance between feedback mechanisms in lipopolysaccharide-induced NF-κB
signaling. Sci Signal 7. doi:10.1126/scisignal.2004764.
Suojala, L., T. Orro, H. Järvinen, J. Saatsi, and S. Pyörälä. 2008. Acute phase response in two
consecutive experimentally induced E. coli intramammary infections in dairy cows. Acta Vet
Scand 50. doi:10.1186/1751-0147-50-18.
Swartz, T.H., and B.J. Bradford. Phytogenics and potential uses for enhancing resilience of
ruminant livestock.
Takeuchi, O., and S. Akira. 2010. Pattern Recognition Receptors and Inflammation. Cell
140:805–820. doi:10.1016/j.cell.2010.01.022.
45
Taylor, C.C., M.S. Allen, and M.S. Allen. 2005. Corn Grain Endosperm Type and Brown Midrib
3 Corn Silage: Site of Digestion and Ruminal Digestion Kinetics in Lactating Cows. American
Dairy Science Association.
Tedesco, D., A. Tava, S. Galletti, M. Tameni, G. Varisco, A. Costa, and S. Steidler. 2004.
Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows. J Dairy Sci 87:2239–
2247. doi:10.3168/jds.S0022-0302(04)70044-2.
Timmermans, S., J. Souffriau, and C. Libert. 2019. A general introduction to glucocorticoid
biology. Front Immunol 10. doi:10.3389/fimmu.2019.01545.
Trimboli, F., M. Ragusa, C. Piras, V. Lopreiato, and D. Britti. 2020. Outcomes from
experimental testing of nonsteroidal anti‐inflammatory drug (Nsaid) administration during the
transition period of dairy cows. Animals 10:1–13. doi:10.3390/ani10101832.
Vane, J., and R. Botting. 1987. Inflammation and the mechanism of action of anti‐inflammatory
drugs. The FASEB Journal 1:89–96. doi:10.1096/fasebj.1.2.3111928.
Vane, J.R., Y.S. Bakhle, and R.M. Botting. 1998. CYCLOOXYGENASES 1 AND 2.
Waghorn, G.C., and W.C. McNabb. 2003. Consequences of plant phenolic compounds for
productivity and health of ruminants. Proceedings of the Nutrition Society 62:383–392.
doi:10.1079/pns2003245.
Walker, C.C.F., L.M. Sordillo, and G.A. Contreras. 2022a. Anandamide Alters Barrier Integrity
of Bovine Vascular Endothelial Cells during Endotoxin Challenge. Antioxidants 11.
doi:10.3390/antiox11081461.
Walker, C.C.F., L.M. Sordillo, and G.A. Contreras. 2022b. Anandamide Alters Barrier Integrity
of Bovine Vascular Endothelial Cells during Endotoxin Challenge. Antioxidants 11:1461.
doi:10.3390/antiox11081461.
Wall, S.K., L.E. Hernández-Castellano, A. Ahmadpour, R.M. Bruckmaier, and O. Wellnitz.
2016. Differential glucocorticoid-induced closure of the blood-milk barrier during
lipopolysaccharide- and lipoteichoic acid-induced mastitis in dairy cows. J Dairy Sci 99:7544–
7553. doi:10.3168/jds.2016-11093.
Wang, J., C. Guo, Z. Wei, X. He, J. Kou, E. Zhou, Z. Yang, and Y. Fu. 2016. Morin suppresses
inflammatory cytokine expression by downregulation of nuclear factor-κB and mitogen-activated
protein kinase (MAPK) signaling pathways in lipopolysaccharide-stimulated primary bovine
mammary epithelial cells. J Dairy Sci 99:3016–3022. doi:10.3168/jds.2015-10330.
46
Wildman, E.E., G.M. Jones, P.E. Wagner, R.L. Boman, H.F. Troutt, and T.N. Lesch. 1982. A
Dairy Cow Body Condition Scoring System and Its Relationship to Selected Production
Characteristics. J Dairy Sci 65:495–501. doi:10.3168/jds.S0022-0302(82)82223-6.
Woodward, S., M. Auldist, P. Laboyrie, and E. Jansen. 1999. Effect of Lotus corniculatus and
condensed tannins on milk yield and milk composition of dairy cows.
Worku, M., and H. Ismail. 2020. A Review of the Effect of Plant-derived Bioactive Substances
on the Inflammatory Response of Ruminants (Sheep, Cattle, and Goats) Biopsia Project View
project Mutation detection View project. doi:10.31021/ijvam.20203130.
Yeiser, E.E., K.E. Leslie, M.L. McGilliard, and C.S. Petersson-Wolfe. 2012. The effects of
experimentally induced Escherichia coli mastitis and flunixin meglumine administration on
activity measures, feed intake, and milk parameters. J Dairy Sci 95:4939–4949.
doi:10.3168/jds.2011-5064.
Yoza, B.K., and C.E. McCall. 2011. Facultative heterochromatin formation at the IL-1 beta
promoter in LPS tolerance and sepsis. Cytokine 53:145–152. doi:10.1016/j.cyto.2010.10.007.
Zachut, M., G. Kra, U. Moallem, L. Livshitz, Y. Levin, S. Udi, A. Nemirovski, and J. Tam.
2018. Characterization of the endocannabinoid system in subcutaneous adipose tissue in
periparturient dairy cows and its association to metabolic profiles. PLoS One 13.
doi:10.1371/journal.pone.0205996.
Zielińska, D., H. Zieliński, J.M. Laparra-Llopis, D. Szawara-Nowak, J. Honke, and J.A.
Giménez-Bastida. 2021. Caffeic acid modulates processes associated with intestinal
inflammation. Nutrients 13:1–15. doi:10.3390/nu13020554.
Ziring, D., B. Wei, P. Velazquez, M. Schrage, N.E. Buckley, and J. Braun. 2006. Formation of B
and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58:714–725.
doi:10.1007/s00251-006-0138-x.
47
TABLES AND FIGURES
APPENDIX
50.70
15.76
25.50
SD
2.455
0.802
1.298
Table 1. Nutrient composition of the total mixed ration fed to lactating dairy cows throughout
the experiment1.
Item, %DM Mean
DM
CP
Starch
ESC2
NDF
Lignin
Crude Fat
Ash
Ca
P
Mg
K
S
Na
Cl
4.64
32.92
3.63
3.79
6.45
0.81
0.38
0.34
1.23
0.19
0.35
0.28
1.369
2.061
0.347
0.256
0.483
0.219
0.109
0.095
0.275
0.011
0.083
0.025
1n = 5 composite samples analyzed
2ESC = ethanol soluble carbohydrates
48
Table 2. Effect of β-Caryophyllene (BCP) on feed intake, milk production, and milk
composition prior to, during, and after intramammary challenges with lipopolysaccharide (LPS).
Treatment
BCP
CON
SEM
P -values
Trt Day Trt × Day Lactgrp2
Item
Pre-challenge
DMI, kg/d
Milk, kg/d
ECM, kg/d
Fat, kg/d
Protein, kg/d
SCS1
Post -challenge 1
DMI, kg/d
Milk, kg/d
ECM, kg/d
Fat, kg/d
Protein, kg/d
SCS1
Post -challenge 2
24.40
35.30
34.97
1.39
1.14
0.52
24.84
30.51
35.40
1.39
1.11
2.12
24.90
37.00
34.67
1.43
1.22
1.07
25.74
33.31
35.30
1.46
1.17
2.85
1.10
2.22
0.60
0.25
0.07
0.35
0.20
3.03
0.80
0.10
0.11
0.36
0.68 <0.01
0.50 <0.01
0.68 <0.01
0.01
0.67
0.75
0.39
0.17
0.14
0.51 <0.01
0.41 <0.01
0.90 <0.01
0.09
0.55
0.54 <0.01
0.06 <0.01
0.26
0.76
0.89
0.81
0.72
0.71
<0.01
0.84
0.72
0.92
0.33
<0.01
0.81
<0.01
<.0001
0.02
0.06
0.28
0.10
0.02
0.96
0.03
0.46
0.96
0.73
0.28
0.63
0.77
0.44
0.63
Milk, kg/d
ECM, kg/d
SCS1
2.71
0.95
0.45
1Somatic cell score (SCS) = log2 (SCC/100,000)+3
2Lactgrp = lactation group, primiparous vs. multiparous
26.86
35.73
8.23
30.00
35.12
7.82
0.38 <0.01
0.53 <0.01
0.29
49
Table 3. Effect of β-caryophyllene (BCP) on acute phase proteins after intramammary
challenges with lipopolysaccharide (LPS).
Item
Treatment SEM P -values
BCP CON
Trt
Time Trt ×
Lactgrp1 BLV
Time
LPS Challenge 1
BHB, mmol/L
Glucose, mg/dL
Haptoglobin, mg/L
Insulin, ng/mL
LBP, mg/L
LPS Challenge 2
0.05
0.59
0.52
72.98 75.06
3.02
79.87 117.88 12.52
0.21
1.33
1.48
1.06
6.49
6.41
BHB, mmol/L
Glucose, mg/dL
Haptoglobin, mg/L
Insulin, ng/mL
LBP, mg/L
0.51
0.49
77.29 76.58
52.38 68.84
1.28
1.38
7.45
6.28
0.03
4.40
14.19
0.19
0.80
0.16
0.50
<0.01
0.50
0.95
0.42
0.87
0.26
0.47
0.16
<0.01 <.04
0.96
<0.01
0.22
<0.01
0.78
<0.01
0.11
<0.01
<0.01
0.39
<0.01
<0.01
<0.01
0.79
0.39
0.38
0.13
0.67
0.92
0.56
0.01
0.76
0.49
0.60
0.53
0.80
0.29
0.03
0.26
0.13
0.63
0.42
0.87
0.28
0.55
0.82
0.51
0.66
1Lactgrp = lactation group, primiparous vs. multiparous
Table 4. Effect of β-caryophyllene (BCP) on the area under the curve of acute phase proteins
and body temperature after intramammary challenges with lipopolysaccharide (LPS). All
reported values are relative to the basal period.
LPS Challenge
P -values
Item
First
Second
SEM
Trt Lactgrp BLV Challenge
0.84
-1.75
-3.17
BHB
-140.61 0.64
-28.61
Glucose
0.06
45739
543291
Haptglobin
0.95
5.06
18.29
Insulin
0.75
28955
496314
LBP
Body Temp
0.29
50.65
538.88
1Lactgrp = lactation group, primiparous vs. multiparous
-1.42
112.00
353952
19.22
444139
552.52
0.37
0.57
<.01
0.86
0.75
0.29
0.41
0.02
<.01
0.78
0.35
0.11
0.3
0.71
0.64
0.39
0.96
0.9
50
Table 5. Effect of β-caryophyllene (BCP) on bodyweight and body condition score change in
late lactation cows challenged with intramammary lipopolysaccharide (LPS).
Item
Treatment
BCP CON
SEM
P -values
Trt Week Trt × Week Lactgrp2 BLV
BW, kg/d
692.81 718.64
28.33
0.37 <0.01
BCS, units/wk1
1Measured on a 1-5 scale (Wildman et al., 1982)
2Lactgrp = lactation group, primiparous vs. multiparous
3.33
3.29
0.04
0.81
0.18
0.75
0.46
<0.01
0.48
0.8
0.32
51
Figure 1. Effect of β-caryophyllene (BCP) on intravaginal body temperature after the first
lipopolysaccharide challenge. The solid vertical line indicates the time of the lipopolysaccharide
challenge. Supplementing BCP did not affect body temperature after the first lipopolysaccharide
challenge (P = .83).
52
Figure 2. Effect of β-Caryophyllene (BCP) on body temperature after the second
lipopolysaccharide challenge. BCP was not supplemented during the second lipopolysaccharide
challenge. the solid vertical line indicates the time of the lipopolysaccharide challenge.
Supplementing BCP did not affect body temperature after the second lipopolysaccharide
challenge (P = .81).
53
Figure 3. Composite somatic cell score (SCS = log2 [SCC / 100,000] + 3) of dairy cows fed β-
caryophyllene (BCP) or a no-treatment control (CON). Cows were challenged with
lipopolysaccharide in their right rear mammary gland, and results are shown for the challenged
quarter. Treatment tended to affect SCS (P = 0.06), and there was a significant treatment × time
interaction (P < 0.01), reflecting a tendency for BCP to reduce SCS relative to CON on d 24
post-challenge (P = 0.06).
54
Figure 4. Quarter level somatic cell score somatic cell score (SCS = log2 [SCC / 100,000] + 3)
of dairy cows fed β-caryophyllene (BCP) or a no-treatment control (CON). Cows were
challenged a second time with lipopolysaccharide in their right rear quarter. Treatment did not
affect SCS (P = 0.43). There was a significant effect of BCP supplementation (P < 0.01) at 16
hours post challenge (P < 0.01).
55